177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide
Bioorganic & Medicinal Chemistry · 2024
DOI: 10.1016/j.bmc.2024.117883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2024. Verfasst von Sushree Arpitabala Yadav und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India. Hauptthemen laut MEDLINE: Lutetium, Erb-b2 Receptor Tyrosine Kinases, Nuclear Localization Signals, Radioisotopes. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Tagging of cell permeable nuclear localization sequence (NLS) with receptor targeting peptide vectors is an attractive strategy for selectively targeted translocation of therapeutic cargoes. The present study aimed at grafting nuclear localization sequence (NLS) onto breast cancer targeting rL-A9 peptide. Molecular docking analysis revealed higher binding affinity of the peptide, DOTA-NLS-rL-A9 (-26.1 kJ/mol) towards HER2 receptor in comparison to DOTA-rL-A9 peptide (-22.2 kJ/mol). Confocal microscopy data suggested significantly enhanced cellular internalization of NLS-tagged peptide. The engineered HER2-selective, DOTA-NLS-rL-A9 peptide scaffold was radiolabeled with Lu-177 for intracellular delivery of the theranostic radionuclide into tumor cells. [177Lu]Lu-DOTA-NLS-rL-A9 exhibited significantly enhanced binding affinity (4.58 ± 1.77 nM) towards human breast carcinoma SKBR3 cells and cellular internalization (85 % at 24 h) compared to its original analog, [177Lu]Lu-DOTA-rL-A9. In vivo biodistribution studies showed consistent retention of [177Lu]Lu-DOTA-NLS-rL-A9 in the tumor with negligible washout of radioactivity (∼4.1 % ID/g at 48 h). Prolonged tumor activity with rapid off-target tissue clearance resulted in significantly high tumor-to-background ratios. The radiopeptide, [177Lu]Lu-DOTA-NLS-rL-A9 thus, being precisely confined into HER2-expressing tumor cells and exhibiting favourable pharmacokinetic features is an efficient candidate for further screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India.
- Bio-organic Division, Bhabha Atomic Research Centre, Mumbai, India.
- Protein Crystallography Section, Bio-Science Group, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India.
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: drishtys@barc.gov.in.
Zitieren
APA
Yadav, S. A., Vats, V. K., Sharma, R., Chauhan, N., Subramanian, M., Das, A., & Satpati, D. (2024). 177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2024.117883
Vancouver
Yadav SA, Vats VK, Sharma R, Chauhan N, Subramanian M, Das A, et al. 177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide. Bioorganic & Medicinal Chemistry. 2024. doi:10.1016/j.bmc.2024.117883
BibTeX
@article{Yadav2024,
author = {Yadav, Sushree Arpitabala and Vats, V Kusum and Sharma, Rohit and Chauhan, Nitish and Subramanian, Mahesh and Das, Amit and Satpati, Drishty},
title = {177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide},
journal = {Bioorganic & Medicinal Chemistry},
year = {2024},
doi = {10.1016/j.bmc.2024.117883}
}
EUVIMED